Antroquinonol for Metastatic Pancreatic Cancer as First-Line Treatment

Model: Antroquinonol for Pancreatic Cancer

Booth No: L318

Characteristic

Golden Biotechnology Corp, an advanced biopharma dedicated to innovative new drugs. The new drug, Antroquinonol (HOCENA), a NCE with multi-functions, it can inhibit Ras targeting pathway and PI3K/Akt/mTOR pathway. Antroquinonol has completed Phase 2 trials in NSCLC, AML, pancreatic cancer and COVID-19. Interim report of Phase 2 trial for first-line treatment of meta. pancreatic cancer shows much longer OS than standard therapy. It has received orphan drug designation (ODD) from the FDA for AML, pancreatic cancer, and HCC and for pancreatic cancer in EU. GoldenBiotech welcomes inquiries and discussions from potential partners.

Menu

Antroquinonol for Metastatic Pancreatic Cancer as First-Line Treatment

Characteristic

Other Products

Products you may be interested in

Highest Rated Products